Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ICU Medical manufactures infusion therapy systems, IV solutions, and critical care consumables used in hospitals and alternate care settings globally. The company operates through two segments: Consumables (infusion sets, needleless connectors, closed system transfer devices) and Infusion Systems (smart pumps and software), with significant exposure to hospital capital equipment cycles and recurring consumable revenue streams. Competitive position centers on proprietary Clave needleless connector technology and integrated infusion pump platforms.
ICU Medical generates revenue through a razor-razorblade model where capital equipment (infusion pumps at $3,000-$8,000 per unit) creates installed base for high-margin consumables (connectors at $1-$5 per unit, infusion sets). Pricing power derives from switching costs in hospital formularies, regulatory barriers (510k clearances, CE marks), and integration with electronic medical records. Gross margins compressed by manufacturing complexity and competitive pricing pressure in commoditized IV solution segment acquired from Pfizer/Hospira. Operating leverage limited by R&D requirements for smart pump software updates and regulatory compliance costs.
Hospital capital equipment spending trends and GPO contract wins/losses for Plum 360 infusion pump platform
Consumables volume growth driven by hospital admissions, surgical procedures, and chemotherapy infusion volumes
Gross margin trajectory reflecting resin input costs, manufacturing efficiency, and pricing dynamics in IV solutions segment
Integration progress and cost synergies from Smiths Medical acquisition (completed 2022), targeting $50M+ annual synergies
FDA regulatory actions on infusion pump safety, software updates, and competitive product approvals
Commoditization pressure in IV solutions and basic infusion sets as biosimilars and generic competition intensify, compressing margins in lower-value product lines
Regulatory burden from FDA infusion pump cybersecurity requirements and software validation standards, requiring ongoing R&D investment without revenue upside
Shift toward outpatient and home infusion settings reducing acute care hospital utilization, though partially offset by alternate site opportunities
Baxter International and B. Braun dominate infusion pump installed base with entrenched hospital relationships and broader product portfolios including IV solutions manufacturing
BD (Becton Dickinson) leads in IV catheter and connector technology with Nexiva platform, competing directly with Clave connector franchise
Private equity-backed competitors (Fresenius Kabi) expanding in IV compounding and infusion services, vertically integrating to capture margin
Elevated debt levels ($1.2B term loan) from Smiths Medical acquisition with covenant requirements, limiting financial flexibility for M&A or share repurchases
Negative net margin (-4.9%) and minimal ROE (-0.4%) reflect integration costs and operational challenges, requiring margin recovery to sustain debt service
Working capital intensity with $500M+ inventory (finished goods, work-in-process) exposed to resin price volatility and product obsolescence risk
moderate - Consumables revenue (~65% of mix) exhibits defensive characteristics tied to non-discretionary hospital utilization, while capital equipment sales (~35%) are cyclical and sensitive to hospital system profitability and capital budgets. Elective procedure volumes correlate with employment levels and insurance coverage. International exposure adds sensitivity to European healthcare budgets and emerging market growth.
Rising rates create headwinds through: (1) higher cost of debt servicing on $1.2B term loan from Smiths Medical acquisition, (2) hospital system capital budget constraints as financing costs increase for equipment purchases, (3) valuation multiple compression for med-tech stocks as discount rates rise. Current 0.64x debt/equity manageable but interest expense material at current SOFR levels. Rate cuts would benefit capital equipment demand and reduce financing burden.
Moderate exposure to hospital system credit quality and payment cycles. Customer concentration in large IDNs (Integrated Delivery Networks) and GPOs creates accounts receivable risk if hospital financial stress emerges. Days sales outstanding typically 60-75 days. Minimal direct consumer credit exposure as sales are B2B institutional.
value - Stock trades at 1.6x P/S and 1.8x P/B with depressed margins, attracting investors betting on operational turnaround and margin recovery to historical 10%+ operating margins. Recent 24% six-month rally suggests momentum emerging as integration progresses. Not a growth story given 5.4% revenue growth and mature market dynamics. Minimal dividend (FCF prioritized for debt paydown), so not income-focused.
moderate-high - Medical device stocks exhibit beta of 0.8-1.2 to broader market. ICUI specific volatility elevated due to: (1) integration execution risk from Smiths Medical deal, (2) quarterly earnings volatility from lumpy capital equipment orders, (3) smaller market cap ($3.8B) with lower institutional ownership and liquidity. Recent 1-year return of -6.5% vs +14% over 3 months shows elevated swing potential.
